OPKO Health, Inc. - 10-Q Summary (Period Ended June 30, 2008)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for OPKO Health, Inc., a specialty healthcare company focused on ophthalmic pharmaceuticals, imaging, and diagnostic systems. The reporting period covers the three and six months ended June 30, 2008. The company is a non-accelerated filer with 184,651,391 shares of common stock outstanding as of July 30, 2008.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenue | $0.9 million | $3.7 million |
| Gross Margin (Deficit) | ($0.1) million | ($0.7) million |
| Operating Loss | ($10.7) million | ($21.3) million |
| Net Loss | ($10.9) million | ($21.8) million |
| Net Loss Attributable to Common Shareholders | ($10.9) million | ($21.9) million |
| Cash and Cash Equivalents (End of Period) | $5.5 million | |
| Net Cash Used in Operating Activities | ($15.5) million (Six Months) | |
| Total Debt (Line of Credit) | $12.0 million (Fully Utilized) |
Material Changes vs. Prior Period
- Revenue Generation: The company generated revenue for the first time in its history ($3.7 million for six months), derived entirely from the sale of ophthalmic instrumentation products by its subsidiary, Ophthalmic Technologies, Inc. (OTI). The prior year periods showed $0 revenue.
- Acquisition Activity: On May 6, 2008, OPKO acquired Vidus Ocular, Inc. for approximately $1.3 million in stock. This resulted in a $1.4 million write-off of acquired in-process research and development (IPR&D). In contrast, the prior year included a massive $243.8 million IPR&D write-off from the acquisition of Acuity Pharmaceuticals.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased to $3.2 million for the quarter (from $5.3 million in 2007), primarily due to a reduction in stock-based compensation. Research and development (R&D) expenses remained relatively flat at $5.5 million for the quarter.
- Cash Position: Cash and cash equivalents declined significantly from $23.4 million at December 31, 2007, to $5.5 million at June 30, 2008, driven by operating losses and debt repayments.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Warning: Management explicitly states that current cash ($5.5 million) is insufficient to meet anticipated cash requirements for operations and debt service for the next 12 months. Additional funding is required in the first half of 2009.
- Subsequent Financing: On August 8, 2008, the company agreed to a $15 million investment from a group including The Frost Group (related party) in exchange for 13.5 million shares at $1.11 per share.
- Regulatory Issues: The FDA issued a warning letter to OTI regarding quality system deficiencies at its Toronto facility. This has resulted in an Import Alert, preventing the sale of certain OTI products (Scan 1000, Scan 2000, OCT/SLO) in the U.S. until violations are corrected.
- Legal Proceedings: The company is defending against a lawsuit filed by Ophthalmic Imaging Systems seeking over $7 million in damages for alleged tortious interference and aiding and abetting.
- Outlook: Revenue is expected to increase in the second half of 2008 and first half of 2009 as manufacturing transitions in-house and U.S. sales of the OCT/SLO product commence pending FDA clearance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $15 million subsequent financing to cover the projected cash burn rate through the first half of 2009.
- FDA Resolution: Monitor the status of the FDA warning letter and the timeline for resolving quality system deficiencies to enable U.S. sales of OTI products.
- Bevasiranib Progress: Track the status and costs of the ongoing Phase III clinical trial for the lead drug candidate, bevasiranib.
- Related Party Transactions: Review the terms of the $12 million line of credit and the $15 million equity investment involving The Frost Group and company executives.
- Legal Exposure: Assess the potential financial impact of the $7 million lawsuit filed by Ophthalmic Imaging Systems.